HomeInsightsStock Comparison

Divis Laboratories Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Divis Laboratories Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Last Updated on: May 12, 2025

Key Highlights

  • The Latest Trading Price of Divis Laboratories Ltd is ₹ 5893 as of 12 May 09:52.
  • The P/E Ratio of Divis Laboratories Ltd changed from 38.3 on March 2020 to 56.9 on March 2024 . This represents a CAGR of 8.24% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 22.5 on March 2020 to 40.6 on March 2024 . This represents a CAGR of 12.53% over 5 years.
  • The Market Cap of Divis Laboratories Ltd changed from ₹ 52763 crore on March 2020 to ₹ 91234 crore on March 2024 . This represents a CAGR of 11.57% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 388812 crore on March 2024 . This represents a CAGR of 35.70% over 5 years.
  • The revenue of Divis Laboratories Ltd for the Dec '24 is ₹ 2401 crore as compare to the Sep '24 revenue of ₹ 2444 crore. This represent the decline of -1.76% The revenue of Sun Pharmaceutical Industries Ltd for the Dec '24 is ₹ 14141 crore as compare to the Sep '24 revenue of ₹ 13645 crore. This represent the growth of 3.63%.
  • The ebitda of Divis Laboratories Ltd for the Dec '24 is ₹ 825 crore as compare to the Sep '24 ebitda of ₹ 822 crore. This represent the growth of 0.36% The ebitda of Sun Pharmaceutical Industries Ltd for the Dec '24 is ₹ 4158 crore as compare to the Sep '24 ebitda of ₹ 4292 crore. This represent the decline of -3.13%.
  • The net profit of Divis Laboratories Ltd changed from ₹ 356 crore to ₹ 589 crore over 7 quarters. This represents a CAGR of 33.34% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2013 crore to ₹ 2917 crore over 7 quarters. This represents a CAGR of 23.62% .
  • The Dividend Payout of Divis Laboratories Ltd changed from 33.04 % on March 2020 to 50.44 % on March 2024 . This represents a CAGR of 8.83% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 29.89 % on March 2020 to 113.33 % on March 2024 . This represents a CAGR of 30.55% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Divis Laboratories Ltd

  • Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
  • The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
  • It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
  • In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
  • It is among the largest pharmaceutical companies in India with a portfolio of approx.

About Sun Pharmaceutical Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Divis Laboratories Ltd News Hub

News

Divis Laboratories to conduct board meeting

Divis Laboratories will hold a meeting of the Board of Directors of the Company on 17 May ...

Read more

08 May 2025 15:24

News

Divis Lab spurts as broker maintains buy call

In its latest note, the broker highlighted Divi's strong potential to emerge as a primary ...

Read more

24 Apr 2025 13:45

News

Divis Labs jumps on signing long-term manufacturing pact with global pharma major

In a regulatory filing on 18 April 2025, Divi's stated that the agreement pertains to the ...

Read more

21 Apr 2025 10:18

News

Divis Laboratories enters into long term manufacturing and supply agreement

Divis Laboratories has signed a long term manufacturing and supply agreement with a global...

Read more

18 Apr 2025 10:02

News

Divi's Laboratories announces change in senior management

Divi's Laboratories announced that G. Bala Kishore, serving as General Manager (EHS) of th...

Read more

31 Mar 2025 10:14

News

Volumes jump at Divis Laboratories Ltd counter

IndusInd Bank Ltd, Axis Bank Ltd, Gujarat State Petronet Ltd, Kaynes Technology India Ltd ...

Read more

12 Mar 2025 11:00

Sun Pharmaceutical Industries Ltd News Hub

News

Sun Pharmaceutical Industries Ltd Slips 5.32%

Sun Pharmaceutical Industries Ltd fell 5.32% today to trade at Rs 1652.1. The BSE Healthca...

Read more

12 May 2025 09:30

News

Sun Pharma and Israel-based Moebius Medical publish two articles on MM-II

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publica...

Read more

24 Apr 2025 09:12

News

Sun Pharmaceutical launches Fexuprazan tablets 40 mg in India

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the bra...

Read more

07 Apr 2025 09:07

News

Sun Pharma launches Fexuprazan tablets 40 mg in India

The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosi...

Read more

07 Apr 2025 10:23

News

Sun Pharma completes acquisition of Antibe Therapeutics Inc., Canada

Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., ...

Read more

18 Mar 2025 15:01

News

Sun Pharma gains as arm acquires Antibe Therapeutics for $4.5 Million

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty...

Read more

18 Mar 2025 12:53

SWOT Analysis Of Divis Laboratories Ltd

Strength

4

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Sun Pharmaceutical Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Divis Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Sun Pharmaceutical Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Divis Laboratories Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Divis Laboratories Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Divis Laboratories Ltd is 159,310 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 418,647 Cr

What are the key factors driving the stock performance of Divis Laboratories Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Divis Laboratories Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Divis Laboratories Ltd and Sun Pharmaceutical Industries Ltd?

As of May 12, 2025, the Divis Laboratories Ltd stock price is INR ₹6001.1. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1744.85.

How do dividend payouts of Divis Laboratories Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Divis Laboratories Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions